Johnson & Johnson (NYSE:JNJ) – Equities research analysts at Jefferies Group upped their FY2018 earnings per share (EPS) estimates for Johnson & Johnson in a note issued to investors on Tuesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings per share of $8.31 for the year, up from their previous forecast of $8.17. Jefferies Group has a “Buy” rating and a $160.00 price target on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2022 earnings at $11.58 EPS.

A number of other analysts have also commented on the company. Citigroup started coverage on Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 price target on the stock. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. UBS Group reiterated a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a report on Saturday, September 30th. Piper Jaffray Companies reiterated a “hold” rating and set a $120.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 4th. Finally, Cowen set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, October 6th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $145.94.

Johnson & Johnson (NYSE JNJ) traded up $0.44 during mid-day trading on Wednesday, hitting $147.36. The stock had a trading volume of 8,705,833 shares, compared to its average volume of 6,040,000. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $148.32. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $395,890.00, a price-to-earnings ratio of 25.58, a PEG ratio of 2.75 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter last year, the company earned $1.68 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis.

A number of large investors have recently added to or reduced their stakes in the business. Stillwater Capital Advisors LLC grew its position in shares of Johnson & Johnson by 1.4% in the second quarter. Stillwater Capital Advisors LLC now owns 89,136 shares of the company’s stock valued at $11,792,000 after purchasing an additional 1,269 shares in the last quarter. Carlton Hofferkamp & Jenks Wealth Management LLC grew its position in shares of Johnson & Johnson by 3.6% in the second quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 18,987 shares of the company’s stock valued at $2,511,000 after purchasing an additional 652 shares in the last quarter. Beacon Financial Group grew its position in shares of Johnson & Johnson by 2.1% in the second quarter. Beacon Financial Group now owns 87,012 shares of the company’s stock valued at $11,541,000 after purchasing an additional 1,814 shares in the last quarter. First Command Bank grew its position in shares of Johnson & Johnson by 4.4% in the second quarter. First Command Bank now owns 11,163 shares of the company’s stock valued at $1,476,000 after purchasing an additional 472 shares in the last quarter. Finally, Stock Yards Bank & Trust Co. grew its position in shares of Johnson & Johnson by 5.7% in the second quarter. Stock Yards Bank & Trust Co. now owns 135,744 shares of the company’s stock valued at $17,957,000 after purchasing an additional 7,347 shares in the last quarter. 65.71% of the stock is owned by institutional investors and hedge funds.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.28%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

ILLEGAL ACTIVITY NOTICE: This story was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://theolympiareport.com/2018/01/19/equities-analysts-issue-forecasts-for-johnson-johnsons-fy2018-earnings-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.